AbbVie's Risankizumab Receives Positive CHMP Opinion for Ulcerative Colitis

Friday, 31 May 2024, 03:12
AbbVie's Risankizumab, branded as SKYRIZI®, has received a favorable opinion from CHMP for the treatment of adults with moderately to severely active ulcerative colitis. This positive development highlights the potential of Risankizumab in addressing the unmet medical needs of patients with this condition. The endorsement by CHMP positions AbbVie for potential market approval, signaling a significant advancement in the field of ulcerative colitis treatment.
https://store.livarava.com/b13ddbb1-1f15-11ef-a3ee-9d5fa15a64d8.jpg
AbbVie's Risankizumab Receives Positive CHMP Opinion for Ulcerative Colitis

AbbVie's Positive CHMP Opinion for Risankizumab (SKYRIZI®)

AbbVie has received a positive opinion from CHMP for Risankizumab, indicated for the treatment of adults with moderately to severely active ulcerative colitis. This development underscores the efficacy and potential impact of Risankizumab in addressing the medical needs of patients with this condition.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Do you want to advertise here?
Do you want to advertise here?
Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe